4/15
09:11 am
prax
Praxis Precision Medicines (PRAX) had its "buy" rating reaffirmed by Deutsche Bank Aktiengesellschaft.
Low
Report
Praxis Precision Medicines (PRAX) had its "buy" rating reaffirmed by Deutsche Bank Aktiengesellschaft.
4/14
11:10 am
prax
Praxis Precision Medicines (PRAX) had its "buy" rating reaffirmed by Needham & Company LLC. They now have a $510.00 price target on the stock.
Low
Report
Praxis Precision Medicines (PRAX) had its "buy" rating reaffirmed by Needham & Company LLC. They now have a $510.00 price target on the stock.
4/14
07:30 am
prax
Praxis Precision Medicines Announces FDA Acceptance of New Drug Application for Ulixacaltamide HCl in Patients with Essential Tremor
Medium
Report
Praxis Precision Medicines Announces FDA Acceptance of New Drug Application for Ulixacaltamide HCl in Patients with Essential Tremor
4/13
08:00 am
prax
Praxis to Showcase Essential3, the First Positive Phase 3 Program in Essential Tremor, at AAN 2026
Low
Report
Praxis to Showcase Essential3, the First Positive Phase 3 Program in Essential Tremor, at AAN 2026
4/11
05:32 am
prax
Praxis Precision Medicines (PRAX) was upgraded by Raymond James Financial, Inc. to "strong-buy".
Low
Report
Praxis Precision Medicines (PRAX) was upgraded by Raymond James Financial, Inc. to "strong-buy".
4/10
09:00 am
prax
Praxis Precision Medicines (PRAX) is now covered by Raymond James Financial, Inc.. They set a "strong-buy" rating and a $815.00 price target on the stock.
Medium
Report
Praxis Precision Medicines (PRAX) is now covered by Raymond James Financial, Inc.. They set a "strong-buy" rating and a $815.00 price target on the stock.
4/7
08:02 am
prax
Praxis Precision Medicines (PRAX) had its "buy" rating reaffirmed by HC Wainwright. They now have a $1,245.00 price target on the stock.
Low
Report
Praxis Precision Medicines (PRAX) had its "buy" rating reaffirmed by HC Wainwright. They now have a $1,245.00 price target on the stock.
4/6
04:15 pm
prax
Praxis: Strong Buy As Relutrigine Submission Accepted Plus Expansion Potential [Seeking Alpha]
Low
Report
Praxis: Strong Buy As Relutrigine Submission Accepted Plus Expansion Potential [Seeking Alpha]
4/6
12:21 pm
prax
Praxis Precision Medicines (PRAX) had its "buy" rating reaffirmed by BTIG Research. They now have a $843.00 price target on the stock.
Low
Report
Praxis Precision Medicines (PRAX) had its "buy" rating reaffirmed by BTIG Research. They now have a $843.00 price target on the stock.
4/6
08:44 am
prax
Praxis Precision Medicines Announces Positive Results from the EMBRAVE Part A Trial of Elsunersen in Patients with SCN2A Early-Onset Developmental and Epileptic Encephalopathy [Yahoo! Finance]
Low
Report
Praxis Precision Medicines Announces Positive Results from the EMBRAVE Part A Trial of Elsunersen in Patients with SCN2A Early-Onset Developmental and Epileptic Encephalopathy [Yahoo! Finance]
4/6
08:00 am
prax
Praxis Precision Medicines Announces Positive Results from the EMBRAVE Part A Trial of Elsunersen in Patients with SCN2A Early-Onset Developmental and Epileptic Encephalopathy
Low
Report
Praxis Precision Medicines Announces Positive Results from the EMBRAVE Part A Trial of Elsunersen in Patients with SCN2A Early-Onset Developmental and Epileptic Encephalopathy
4/5
03:20 pm
prax
A Look At Praxis Precision Medicines (PRAX) Valuation After FDA Priority Review For Relutrigine [Yahoo! Finance]
Low
Report
A Look At Praxis Precision Medicines (PRAX) Valuation After FDA Priority Review For Relutrigine [Yahoo! Finance]
4/2
04:01 pm
prax
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
3/30
04:01 pm
prax
Praxis Precision Medicines Announces FDA Acceptance and Priority Review of New Drug Application for Relutrigine in Patients with SCN2A and SCN8A DEEs
High
Report
Praxis Precision Medicines Announces FDA Acceptance and Priority Review of New Drug Application for Relutrigine in Patients with SCN2A and SCN8A DEEs
3/30
02:07 am
prax
Janus Henderson Triton Fund Q4 2025 Commentary [Seeking Alpha]
Medium
Report
Janus Henderson Triton Fund Q4 2025 Commentary [Seeking Alpha]
3/26
05:49 am
prax
Praxis Precision Medicines (PRAX) was upgraded by Truist Financial Corporation to "strong-buy".
Low
Report
Praxis Precision Medicines (PRAX) was upgraded by Truist Financial Corporation to "strong-buy".
3/18
02:00 pm
prax
Biotech Stock Still Up 700% Despite 30% Drop This Year as One Fund Discloses $9 Million Exit [Yahoo! Finance]
Low
Report
Biotech Stock Still Up 700% Despite 30% Drop This Year as One Fund Discloses $9 Million Exit [Yahoo! Finance]
3/18
03:28 am
prax
Will Extended Cash Runway And Dual FDA Filings Shift Praxis Precision Medicines' (PRAX) Narrative Toward Commercialization? [Yahoo! Finance]
Medium
Report
Will Extended Cash Runway And Dual FDA Filings Shift Praxis Precision Medicines' (PRAX) Narrative Toward Commercialization? [Yahoo! Finance]
3/16
06:50 pm
prax
This Biotech Stock Up 700% Is Still a Top Holding Despite a $9.3 Million Sale Last Quarter [Yahoo! Finance]
Low
Report
This Biotech Stock Up 700% Is Still a Top Holding Despite a $9.3 Million Sale Last Quarter [Yahoo! Finance]
3/15
08:22 am
prax
Is Praxis Precision Medicines (PRAX) Still Attractive After Its Big Share Price Run? [Yahoo! Finance]
Medium
Report
Is Praxis Precision Medicines (PRAX) Still Attractive After Its Big Share Price Run? [Yahoo! Finance]
3/14
01:26 pm
prax
Praxis FDA Filings Shift Focus From Pipeline Promise To Potential Revenue [Yahoo! Finance]
Medium
Report
Praxis FDA Filings Shift Focus From Pipeline Promise To Potential Revenue [Yahoo! Finance]
3/13
10:44 am
prax
Praxis Stock Has Surged 700% in a Year, and This Fund Is Betting $266 Million on Its Pipeline [Yahoo! Finance]
Medium
Report
Praxis Stock Has Surged 700% in a Year, and This Fund Is Betting $266 Million on Its Pipeline [Yahoo! Finance]
3/13
09:54 am
prax
Biotech Stock Up 685% Draws $80.5 Million Investment Amid Dual FDA Filings [Yahoo! Finance]
Medium
Report
Biotech Stock Up 685% Draws $80.5 Million Investment Amid Dual FDA Filings [Yahoo! Finance]
3/9
11:05 am
prax
Praxis Precision Medicines (PRAX) had its "buy" rating reaffirmed by BTIG Research.
Low
Report
Praxis Precision Medicines (PRAX) had its "buy" rating reaffirmed by BTIG Research.
3/4
04:01 pm
prax
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)